Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized active-controlled study of K-LA5 in chronic renal failure patients on hemodialysis
jRCT2080223080Phase 3Completed
- Sponsor
- Fuso Pharmaceutical Industries
- Start
- Jan 2016
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by Fuso Pharmaceutical Industries. Primary endpoints: Efficacy comparison between K-LA5 and Kindaly AF-4 and Safety and tolerability. Started Jan 2016; status: completed.
02
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080223080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223080.